This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sidis, Y. Articles by Schneyer, A. L. Search for Related Content PubMed PubMed Citation Articles by Sidis, Y. Articles by Schneyer, A. L.

Follistatin-Related Protein and Follistatin Differentially Neutralize Endogenous vs. Exogenous Activin

Reproductive Endocrine Unit and National Center for Infertility Research (Y.S., D.V.T., A.L.S.), Massachusetts General Hospital, Boston, Massachusetts 02144; Millennium Pharmaceuticals (W.E.H., Y.P.), Cambridge, Massachusetts 02144; and Endocrine Unit (H.T.K.), Massachusetts General Hospital, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Alan L. Schneyer, Ph.D., Reproductive Endocrine Unit BHX-5, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114. E-mail: . schneyer.alan{at}mgh.harvard.edu

Follistatin-related protein (FSRP) is a new addition to the expanding follistatin (FS)-related gene family whose members contain at least one conserved 10-cysteine follistatin domain. In contrast to other members of this family, FSRP and follistatin also share a common exon/intron domain structure, substantial primary sequence homology, and an ability to irreversibly bind activin. In this study, we further explored the hypothesis that FSRP is a functional as well as structural homologue of FS. N-terminal sequencing of recombinant FSRP revealed that signal peptide cleavage occurs within exon 1, a significant structural difference from FS, in which cleavage occurs at the exon/intron boundary. Solid-phase radioligand competition assays revealed both FS and FSRP to preferentially bind activin with the next closest TGF-ß superfamily member, bone-morphogenic protein-7, being at least 500-fold less potent. Consistent with their similar activin-binding affinities, FSRP and FS both prevented exogenous (endocrine or paracrine) activin from accessing its receptor and inducing gene transcription in bioassays. However, FS was at least 100-fold more potent than FSRP in inhibiting gene transcription and FSH release mediated by endogenously produced (autocrine) activin-A or activin-B in multiple cell systems. Finally, FSRP lacks the heparin-binding sequence found in FS, and we found that it was also unable to bind cell surface heparin sulfated proteoglycans. These findings suggest that structural differences between FSRP and FS may underlie their different neutralizating capabilities with respect to exogenous vs. endogenous activin. Taken together with our previous studies showing that activin binding is essential for FS’s biological activity, the differential activities of FSRP and FS further indicate that activin binding is necessary but not sufficient to account for all of FS’s actions.

This article has been cited by other articles:

				Y. Sidis, A. Mukherjee, H. Keutmann, A. Delbaere, M. Sadatsuki, and A. Schneyer Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins Endocrinology, July 1, 2006; 147(7): 3586 - 3597. [Abstract] [Full Text] [PDF]

				C. A. Harrison, K. L. Chan, and D. M. Robertson Activin-A Binds Follistatin and Type II Receptors through Overlapping Binding Sites: Generation of Mutants with Isolated Binding Activities Endocrinology, June 1, 2006; 147(6): 2744 - 2753. [Abstract] [Full Text] [PDF]

				T. R. Kumar Too Many Follistatins: Racing Inside and Getting Out of the Cell Endocrinology, December 1, 2005; 146(12): 5048 - 5051. [Full Text] [PDF]

				S. Saito, Y. Sidis, A. Mukherjee, Y. Xia, and A. Schneyer Differential Biosynthesis and Intracellular Transport of Follistatin Isoforms and Follistatin-Like-3 Endocrinology, December 1, 2005; 146(12): 5052 - 5062. [Abstract] [Full Text] [PDF]

				G. M. Beattie, A. D. Lopez, N. Bucay, A. Hinton, M. T. Firpo, C. C. King, and A. Hayek Activin A Maintains Pluripotency of Human Embryonic Stem Cells in the Absence of Feeder Layers Stem Cells, April 1, 2005; 23(4): 489 - 495. [Abstract] [Full Text] [PDF]

				Y. Sidis, A. L. Schneyer, and H. T. Keutmann Heparin and Activin-Binding Determinants in Follistatin and FSTL3 Endocrinology, January 1, 2005; 146(1): 130 - 136. [Abstract] [Full Text] [PDF]

				E. del Re, Y. Sidis, D. A. Fabrizio, H. Y. Lin, and A. Schneyer Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System J. Biol. Chem., December 17, 2004; 279(51): 53126 - 53135. [Abstract] [Full Text] [PDF]

				J R V Silva, R van den Hurk, H T A van Tol, B A J Roelen, and J R Figueiredo Gene expression and protein localisation for activin-A, follistatin and activin receptors in goat ovaries J. Endocrinol., November 1, 2004; 183(2): 405 - 415. [Abstract] [Full Text] [PDF]

				A. L. Schneyer, Q. Wang, Y. Sidis, and P. M. Sluss Differential Distribution of Follistatin Isoforms: Application of a New FS315-Specific Immunoassay J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5067 - 5075. [Abstract] [Full Text] [PDF]

				Y. Xia, Y. Sidis, and A. Schneyer Overexpression of Follistatin-Like 3 in Gonads Causes Defects in Gonadal Development and Function in Transgenic Mice Mol. Endocrinol., April 1, 2004; 18(4): 979 - 994. [Abstract] [Full Text] [PDF]

				H. T. Keutmann, A. L. Schneyer, and Y. Sidis The Role of Follistatin Domains in Follistatin Biological Action Mol. Endocrinol., January 1, 2004; 18(1): 228 - 240. [Abstract] [Full Text] [PDF]

				J. Liu, T. Kuulasmaa, V.-M. Kosma, R. Butzow, T. Vanttinen, C. Hyden-Granskog, and R. Voutilainen Expression of Betaglycan, an Inhibin Coreceptor, in Normal Human Ovaries and Ovarian Sex Cord-Stromal Tumors and Its Regulation in Cultured Human Granulosa-Luteal Cells J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5002 - 5008. [Abstract] [Full Text] [PDF]

				X. Wu, S.-T. Pang, L. Sahlin, A. Blanck, G. Norstedt, and A. Flores-Morales Gene Expression Profiling of the Effects of Castration and Estrogen Treatment in the Rat Uterus Biol Reprod, October 1, 2003; 69(4): 1308 - 1317. [Abstract] [Full Text] [PDF]

				H.-Q. Wang, K. Takebayashi, K. Tsuchida, M. Nishimura, and Y. Noda Follistatin-Related Gene (FLRG) Expression in Human Endometrium: Sex Steroid Hormones Regulate the Expression of FLRG in Cultured Human Endometrial Stromal Cells J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4432 - 4439. [Abstract] [Full Text] [PDF]

				J. J. Hill, Y. Qiu, R. M. Hewick, and N. M. Wolfman Regulation of Myostatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains Mol. Endocrinol., June 1, 2003; 17(6): 1144 - 1154. [Abstract] [Full Text] [PDF]

				A. Schneyer, A. Schoen, A. Quigg, and Y. Sidis Differential Binding and Neutralization of Activins A and B by Follistatin and Follistatin Like-3 (FSTL-3/FSRP/FLRG) Endocrinology, May 1, 2003; 144(5): 1671 - 1674. [Abstract] [Full Text] [PDF]

				K. Y. Arai, K. Tsuchida, K. Uehara, K. Taya, and H. Sugino Characterization of Rat Follistatin-Related Gene: Effects of Estrous Cycle Stage and Pregnancy on Its Messenger RNA Expression in Rat Reproductive Tissues Biol Reprod, January 1, 2003; 68(1): 199 - 206. [Abstract] [Full Text] [PDF]

				J. Liu, T. Vanttinen, C. Hyden-Granskog, and R. Voutilainen Regulation of follistatin-related gene (FLRG) expression by protein kinase C and prostaglandin E2 in cultured granulosa-luteal cells Mol. Hum. Reprod., November 1, 2002; 8(11): 992 - 997. [Abstract] [Full Text] [PDF]